<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35508987</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-3658</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular medicine (Cambridge, Mass.)</Title>
          <ISOAbbreviation>Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>NDR1 increases NOTCH1 signaling activity by impairing Fbw7 mediated NICD degradation to enhance breast cancer stem cell properties.</ArticleTitle>
        <Pagination>
          <StartPage>49</StartPage>
          <MedlinePgn>49</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">49</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s10020-022-00480-x</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The existence of breast cancer stem cells (BCSCs) causes tumor relapses, metastasis and resistance to conventional therapy in breast cancer. NDR1 kinase, a component of the Hippo pathway, plays important roles in multiple biological processes. However, its role in cancer stem cells has not been explored. The purpose of this study was to investigate the roles of NDR1 in modulating BCSCs.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The apoptosis was detected by Annexin V/Propidium Iodide staining and analyzed by flow cytometry. BCSCs were detected by CD24/44 or ALDEFLUOR staining and analyzed by flow cytometry. The proliferation ability of BCSCs was evaluated by sphere formation assay. The expression of interested proteins was detected by western blot analysis. The expression of HES-1 and c-MYC was detected by real-time PCR. Notch1 signaling activation was detected by luciferase reporter assay. Protein interaction was evaluated by immunoprecipitation. Protein degradation was evaluated by ubiquitination analysis. The clinical relevance of NDR1 was analyzed by Kaplan-Meier Plotter.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">NDR1 regulates apoptosis and drug resistance in breast cancer cells. The upregulation of NDR1 increases CD24<sup>low</sup>/CD44<sup>high</sup> or ALDEFLUOR<sup>high</sup> population and sphere-forming ability in SUM149 and MCF-7 cells, while downregulation of NDR1 induces opposite effects. NDR1 increased the expression of the Notch1 intracellular domain (NICD) and activated the transcription of its downstream target (HES-1 and c-MYC). Critically, both suppression of Notch pathway activation by DAPT treatment or downregulation of Notch1 expression by shRNA reverses NDR1 enhanced BCSC properties. Mechanically, NDR1 interactes with both NICD or Fbw7 in a kinase activity-independent manner. NDR1 reduces the proteolytic turnover of NICD by competing with Fbw7 for NICD binding, thereby leading to Notch pathway activation. Furthermore, NDR1 might function as a hub to modulate IL-6, TNF-α or Wnt3a induced activation of Notch1 signaling pathway and enrichment of breast cancer stem cells. Moreover, we find that the elevation of NDR1 expression predictes poor survival (OS, RFS, DMFS and PPS) in breast cancer.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study revealed a novel function of NDR1 in regulating BCSC properties by activating the Notch pathway. These data might provide a potential strategy for eradicating BCSC to overcome tumor relapses, metastasis and drug resistance.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Ling-Ling</ForeName>
            <Initials>LL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology of The Eastern Hospital, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wan</LastName>
            <ForeName>Xiao-Yun</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Guangzhou Panyu Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Chun-Qi</ForeName>
            <Initials>CQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Panyu Central Hospital, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Fei-Meng</ForeName>
            <Initials>FM</Initials>
            <Identifier Source="ORCID">0000-0001-8793-6677</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology of The Eastern Hospital, The First Affiliated Hospital, Sun Yat-Sen University, No.58, Zhong Shan Er Lu, Guangzhou, 510080, China. zhengfeimeng@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. zhengfeimeng@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Med</MedlineTA>
        <NlmUniqueID>9501023</NlmUniqueID>
        <ISSNLinking>1076-1551</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497761">NOTCH1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C491614">STK38 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001686" MajorTopicYN="Y">Biological Phenomena</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="Y">Protein Serine-Threonine Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051881" MajorTopicYN="N">Receptor, Notch1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Cancer stem cell</Keyword>
        <Keyword MajorTopicYN="N">Fbw7</Keyword>
        <Keyword MajorTopicYN="N">NDR1</Keyword>
        <Keyword MajorTopicYN="N">NOTCH signaling</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>0</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35508987</ArticleId>
        <ArticleId IdType="pmc">PMC9066784</ArticleId>
        <ArticleId IdType="doi">10.1186/s10020-022-00480-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s10020-022-00480-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ali N, et al.  Forward RNAi screens in primary human hematopoietic stem/progenitor cells. Blood. 2009;113:3690–3695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2670788</ArticleId>
            <ArticleId IdType="pubmed">19188664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. Development. 2011;138:3593–3612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21828089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ando K, et al.  Induction of Notch signaling by tumor necrosis factor in rheumatoid synovial fibroblasts. Oncogene. 2003;22:7796–7803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14586405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5838954</ArticleId>
            <ArticleId IdType="pubmed">29506506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergstralh DT, Dawney NS, St JD. Spindle orientation: a question of complex positioning. Development. 2017;144:1137–1145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28351864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bisikirska BC, et al.  STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma. Oncogene. 2013;32:5283–5291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3715597</ArticleId>
            <ArticleId IdType="pubmed">23178486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray SJ. Notch signalling in context. Nat Rev Mol Cell Biol. 2016;17:722–735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27507209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia. 2004;9:145–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15300010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba S, Ikeda M, Katsunuma K, Ohashi K, Mizuno K. MST2- and Furry-mediated activation of NDR1 kinase is critical for precise alignment of mitotic chromosomes. Curr Biol. 2009;19:675–681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19327996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christian LM. The ADAM family: Insights into Notch proteolysis. Fly (austin) 2012;6:30–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22513479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornils H, Kohler RS, Hergovich A, Hemmings BA. Downstream of human NDR kinases: impacting on c-myc and p21 protein stability to control cell cycle progression. Cell Cycle. 2011;10:1897–1904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21593588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornils H, Kohler RS, Hergovich A, Hemmings BA. Human NDR kinases control G(1)/S cell cycle transition by directly regulating p21 stability. Mol Cell Biol. 2011;31:1382–1395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3135299</ArticleId>
            <ArticleId IdType="pubmed">21262772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15803154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Souza B, Meloty-Kapella L, Weinmaster G. Canonical and non-canonical Notch ligands. Curr Top Dev Biol. 2010;92:73–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4286395</ArticleId>
            <ArticleId IdType="pubmed">20816393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehebauer M, Hayward P, Arias AM. Notch, a universal arbiter of cell fate decisions. Science. 2006;314:1414–1415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17138893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan X, et al.  Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;66:7445–7452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16885340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang X, Adler PN. Regulation of cell shape, wing hair initiation and the actin cytoskeleton by Trc/Fry and Wts/Mats complexes. Dev Biol. 2010;341:360–374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2862085</ArticleId>
            <ArticleId IdType="pubmed">20211163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farnie G, Clarke RB. Mammary stem cells and breast cancer–role of Notch signalling. Stem Cell Rev. 2007;3:169–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17873349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foltz DR, Santiago MC, Berechid BE, Nye JS. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol. 2002;12:1006–1011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12123574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fryer CJ, White JB, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell. 2004;16:509–520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15546612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gyorffy B, et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20020197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hashimoto-Torii K, et al.  Interaction between Reelin and Notch signaling regulates neuronal migration in the cerebral cortex. Neuron. 2008;60:273–284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2913541</ArticleId>
            <ArticleId IdType="pubmed">18957219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hergovich A. The roles of NDR protein kinases in hippo signalling. Genes (Basel) 2016;7(5):21.</Citation>
        </Reference>
        <Reference>
          <Citation>Hergovich A, Stegert MR, Schmitz D, Hemmings BA. NDR kinases regulate essential cell processes from yeast to humans. Nat Rev Mol Cell Biol. 2006;7:253–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16607288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hergovich A, Lamla S, Nigg EA, Hemmings BA. Centrosome-associated NDR kinase regulates centrosome duplication. Mol Cell. 2007;25:625–634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17317633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005;122:421–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16096061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72:7–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2566956</ArticleId>
            <ArticleId IdType="pubmed">17169390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W, et al.  Hippo signaling interactions with Wnt/beta-catenin and Notch signaling repress liver tumorigenesis. J Clin Invest. 2017;127:137–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5199712</ArticleId>
            <ArticleId IdType="pubmed">27869648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216–233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2827930</ArticleId>
            <ArticleId IdType="pubmed">19379690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamar E, et al.  Nrarp is a novel intracellular component of the Notch signaling pathway. Genes Dev. 2001;15:1885–1899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC312752</ArticleId>
            <ArticleId IdType="pubmed">11485984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Hibbs MA, Gard AL, Shylo NA, Yun K. Genome-wide analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of Wnt, SHH, and hippo pathway effectors by Notch1. Stem Cells. 2012;30:741–752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3734558</ArticleId>
            <ArticleId IdType="pubmed">22232070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C, et al.  NDR1 protein kinase promotes IL-17- and TNF-alpha-mediated inflammation by competitively binding TRAF3. EMBO Rep. 2017;18:586–602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5376972</ArticleId>
            <ArticleId IdType="pubmed">28219902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011;10:1378–1384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21552008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30:1–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4701972</ArticleId>
            <ArticleId IdType="pubmed">26728553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohini L, Rangarajan A. AMPK promotes Notch1 stability to potentiate hypoxia-induced breast cancer stemness and drug resistance. BioRxiv. 2018 doi: 10.1101/458489v4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/458489v4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moriyama M, et al.  Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J Cell Biol. 2006;173:333–339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2063834</ArticleId>
            <ArticleId IdType="pubmed">16651378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberg C, et al.  The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem. 2001;276:35847–35853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11461910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palomero T, et al.  NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103:18261–18266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1838740</ArticleId>
            <ArticleId IdType="pubmed">17114293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19:491–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3124840</ArticleId>
            <ArticleId IdType="pubmed">20951342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JH, Shin JE, Park HW. The role of hippo pathway in cancer stem cell biology. Mol Cells. 2018;41:83–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5824027</ArticleId>
            <ArticleId IdType="pubmed">29429151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu L, et al.  Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J Biol Chem. 2000;275:35734–35737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10940313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3:756–767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14570040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 2007;67:1879–1882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17332312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26742998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slemmons KK, et al.  A Novel Notch-YAP circuit drives stemness and tumorigenesis in embryonal rhabdomyosarcoma. Mol Cancer Res. 2017;15:1777–1791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5755394</ArticleId>
            <ArticleId IdType="pubmed">28923841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Y, et al.  Interleukin-6 (IL-6) activates the NOTCH1 signaling pathway through E-proteins in endometriotic lesions. J Clin Endocrinol Metab. 2020;105(5):1316–1326.</Citation>
        </Reference>
        <Reference>
          <Citation>Tamaskovic R, Bichsel SJ, Hemmings BA. NDR family of AGC kinases–essential regulators of the cell cycle and morphogenesis. FEBS Lett. 2003;546:73–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12829239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschaharganeh DF, et al.  Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144:1530–1542.e1512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3665638</ArticleId>
            <ArticleId IdType="pubmed">23419361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R, et al.  Notch and Wnt/beta-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget. 2016;7:5754–5768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4868719</ArticleId>
            <ArticleId IdType="pubmed">26735577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu N, et al.  The Hippo signaling functions through the Notch signaling to regulate intrahepatic bile duct development in mammals. Lab Invest. 2017;97:843–853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5901959</ArticleId>
            <ArticleId IdType="pubmed">28581486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan M, et al.  Regulation of NDR1 activity by PLK1 ensures proper spindle orientation in mitosis. Sci Rep. 2015;5:10449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4460818</ArticleId>
            <ArticleId IdType="pubmed">26057687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci. 2005;8:709–715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15917835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Poulton J, Huang YC, Deng WM. The hippo pathway promotes Notch signaling in regulation of cell differentiation, proliferation, and oocyte polarity. PLoS ONE. 2008;3:e1761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2258146</ArticleId>
            <ArticleId IdType="pubmed">18335037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue J, et al.  Downregulation of NDR1 contributes to metastasis of prostate cancer cells via activating epithelial-mesenchymal transition. Cancer Med. 2018 doi: 10.1002/cam4.1532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1532</ArticleId>
            <ArticleId IdType="pmc">PMC6143945</ArticleId>
            <ArticleId IdType="pubmed">30058192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng F, et al.  Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nat Commun. 2016;7:10180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4735655</ArticleId>
            <ArticleId IdType="pubmed">26782714</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
